Back to top
more

Dentsply Sirona (XRAY)

(Delayed Data from NSDQ)

$23.34 USD

23.34
2,836,056

-0.15 (-0.64%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $23.33 -0.01 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

DENTSPLY SIRONA (XRAY) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) fourth-quarter performance to reflect better-than-expected performance at Technology & Equipment and growth in emerging markets.

Dentsply International (XRAY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Dentsply (XRAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Abbott's Alliance With Insulet to Fortify Diabetic Care Unit

by Zacks Equity Research

Both Abbott (ABT) and Insulet will use a pay-as-you-go model to enhance customer acceptance.

Integra LifeSciences Grows Organically Amid Supply Issues

by Zacks Equity Research

Integra LifeSciences' (IART) Codman Specialty Surgical segment registers impressive organic growth in Q4.

Integer Holdings Acquires Inomec, Extends Global Foothold

by Zacks Equity Research

Integer Holdings' (ITGR) Inomec buyout is likely to boost R&D pipeline and also strengthen and expand global foothold.

Here's Why You Should Hold on to Cerner (CERN) Stock Now

by Zacks Equity Research

Cerner (CERN) is gaining traction from prudent strategic deals and big data based EHR system. However, weak margins remain a woe.

Here's Why You Should Invest in Cardinal Health Stock Now

by Zacks Equity Research

Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment.

Sreyoshi Mukherjee headshot

Bleak Outlook for Medical Dental Supplies Industry

by Sreyoshi Mukherjee

Despite digital dentistry and AI being dominant market trends, near-term prospects of the Dental industry look dull.

XRAY or CNMD: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

XRAY vs. CNMD: Which Stock Is the Better Value Option?

Can Solid IC Growth Aid Boston Scientific (BSX) Q4 Earnings?

by Zacks Equity Research

Banking on an innovative portfolio across structural heart and coronary therapies, Boston Scientific's (BSX) IC business is expected to have registered strong sales in Q4.

What's in the Cards for Zimmer Biomet (ZBH) in Q4 Earnings?

by Zacks Equity Research

Gains from developments in business segments are likely to get reflected in Zimmer Biomet's (ZBH) revenue results for the fourth quarter and 2019.

What's in Store for Thermo Fisher (TMO) in Q4 Earnings?

by Zacks Equity Research

Strength in segments is expected to get reflected in Thermo Fisher's (TMO) fourth-quarter and 2019 top-line numbers.

Can Sequencing Products Aid Illumina (ILMN) in Q4 Earnings?

by Zacks Equity Research

Illumina (ILMN) is upbeat about fourth-quarter and fiscal 2019 results after a strong third-quarter performance.

Dentsply (XRAY) Soars to 52-Week High, Time to Cash Out?

by Zacks Equity Research

Dentsply (XRAY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Sweta Killa headshot

10 Top-Ranked S&P 500 Stocks Outperforming in 2020

by Sweta Killa

The rally has been broad based and there are winners across various corners of the space.

Masimo Posts Solid Preliminary 2019 Results, Issues Guidance

by Zacks Equity Research

Higher revenues and upbeat 2020 outlook benefit Masimo's (MASI) preliminary full-year 2019 results.

Baxter Posts Upbeat Q4 Preliminary Results, Issues Guidance

by Zacks Equity Research

Higher revenues, growth in all geographic segments and six business units benefit Baxter's (BAX) Q4 preliminary operating results.

Here's Why You Should Hold on to Cardinal Health Stock Now

by Zacks Equity Research

Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment. However, integration risks remain a concern.

Intuitive Surgical (ISRG) Up on Solid Preliminary Q4 Results

by Zacks Equity Research

Higher revenues and growth in worldwide da Vinci procedure volume benefit Intuitive Surgical's (ISRG) preliminary Q4 results.

Veeva Systems Boosts Product Portfolio With New Application

by Zacks Equity Research

Veeva Systems (VEEV) introduces Veeva Vault Payments, which is likely to bolster the company's already robust product portfolio.

Here's Why You Should Invest in HMS Holdings (HMSY) Stock Now

by Zacks Equity Research

HMS Holdings (HMSY) is gaining traction from the growing PI and TPM analytical services.

Here's Why You Should Retain Surmodics (SRDX) Stock for Now

by Zacks Equity Research

Surmodics (SRDX) is gaining from continued strength at Medical Devices unit and persistent efforts to boost R&D functionalities. However, weak performance at Surmodics' IVD unit remains a concern.

XRAY or ALGN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

XRAY vs. ALGN: Which Stock Is the Better Value Option?

Why Is Dentsply (XRAY) Up 1.7% Since Last Earnings Report?

by Zacks Equity Research

Dentsply (XRAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sriparna Ghosal headshot

3 Orthodontic Stocks to Keep an Eye On

by Sriparna Ghosal

Growth in the orthodontics market has been primarily led by rising focus of vendors on emerging markets, such as Asia-Pacific and LAMEA.